BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy

Journal of Clinical Oncology

Volumn 26, Issue 1, 2008, Pages 26-31

  Malacrida, Sandro ^a   Agata, Simona ^a   Callegaro, Monia ^a   Casella, Cinzia ^a   Barana, Daniela ^a   Scaini, Maria C ^a   Manoukian, Siranoush ^a   Oliani, Cristina ^a   Radice, Paolo ^a   Barile, Monica ^a   Menin, Chiara ^a   D'Andrea, Emma ^a   Montagna, Marco ^a  

^a FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; VALINE;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CAUSAL ATTRIBUTION; CONTROLLED STUDY; GENE DELETION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PATHOGENICITY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EXONS; FEMALE; GENE AMPLIFICATION; GENES, BRCA1; HUMANS; ITALY; LOSS OF HETEROZYGOSITY; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PEDIGREE; POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 37849010906     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.2118     Document Type: Article

References (22)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71, 1994
2. Chenevix-Trench G, Healey S, Lakhani S, et al: Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66:2019-2027, 2006
3. Judkins T, Hendrickson BC, Deffenbaugh AM, et al: Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations. Cancer Res 65:10096-10103, 2005
4. Thompson D, Easton DF, Goldgar DE: A full-likelihood method for the evaluation of causality of sequence variants from family data. Am J Hum Genet 73:652-655, 2003
5. Abkevich V, Zharkikh A, Deffenbaugh AM, et al: Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 41:492-507, 2004
6. Tavtigian SV, Deffenbaugh AM, Yin L, et al: Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43: 295-305, 2006
7. Carvalho MA, Marsillac SM, Karchin R, et al: Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res 67:1494-1501, 2007
8. Morris JR, Pangon L, Boutell C, et al: Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Hum Mol Genet 15:599-606, 2006
9. Osorio A, Milne RL, Honrado E, et al: Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information. Hum Mutat 28:477-485, 2007
10. Federico M, Maiorana A, Mangone L, et al: Identification of families with hereditary breast and ovarian cancer for clinical and mammographic surveillance: The Modena Study Group proposal. Breast Cancer Res Treat 55:213-221, 1999
11. Montagna M, Dalla Palma M, Menin C, et al: Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families. Hum Mol Genet 12: 1055-1061, 2003
12. Goldgar DE, Easton DF, Deffenbaugh AM, et al: Integrated evaluation of DNA sequence variants of unknown clinical significance: Application to BRCA1 and BRCA2. Am J Hum Genet 75:535-544, 2004
13. Montagna M, Santacatterina M, Corneo B, et al: Identification of seven new BRCA1 germline mutations in Italian breast and breast/ovarian cancer families. Cancer Res 56:5466-5469, 1996
14. Marroni F, Aretini P, D'Andrea E, et al: Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet 41:278-285, 2004
15. Finch A, Beiner M, Lubinski J, et al: Salpingooophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296:185-192, 2006
16. Agata S, Viel A, Della Puppa L, et al: Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations. Genes Chromosomes Cancer 45: 791-797, 2006
17. Montagna M, Santacatterina M, Torri A, et al: Identification of a 3 kb Alu-mediated BRCA1 gene rearrangement in two breast/ovarian cancer families. Oncogene 18:4160-4165, 1999
18. Agata S, Dalla Palma M, Callegaro M, et al: Large genomic deletions inactivate the BRCA2 gene in breast cancer families. J Med Genet 42:e64, 2005
19. Karchin R, Monteiro AN, Tavtigian SV, et al: Functional impact of missense variants in BRCA1 predicted by supervised learning. PLoS Comput Biol 3:e26, 2007
20. Vallon-Christersson J, Cayanan C, Haraldsson K, et al: Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 10:353-360, 2001
21. Aretini P, D'Andrea E, Pasini B, et al: Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation. Breast Cancer Res Treat 81:71-79, 2003
22. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003